KRAS-targeting PCAIs halt pancreatic cancer cell migration in lab study

Researchers at Florida A&M University tested polyisoprenylated cysteinyl amide inhibitors (PCAIs) against pancreatic cancer cells to disrupt mutant KRAS signaling. The leading compound NSL-YHJ-2-27 blocked more than 90% of cell migration at low concentrations, altered gene and protein markers related to movement, disrupted actin filaments, and dismantled 3D mini-tumor models; however, these findings are limited to lab studies and require animal testing and safety assessment before any human trials.